Eltrombopag PfOS

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Primary Immune Thrombocytopenia (ITP)Purpura, Thrombocytopenic, Idiopathic

Phase 3

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

CompletedNCT02201290

Novartis PharmaceuticalsPurpura, Thrombocytopenic, Idiopathic

Start: 2013-06-18End: 2017-07-04Updated: 2019-07-05

Unknown Phase

rhTPO Dose Escalation vs Eltrombopag Switch in ITP

Not yet recruitingNCT07476846

Institute of Hematology & Blood Diseases Hospital, ChinaPrimary Immune Thrombocytopenia (ITP)

Start: 2026-06-01End: 2028-03-01Target: 112Updated: 2026-07-01